Rahman Md Arifur, Islam Md Monirul, Ali Md Eunus, Islam Mohammad Ariful, Afroze Farhana, Hossain Mohammad Shamim, Rus'd Ahmed Abu
Department of Microbiology, Jagannath University, Dhaka, Bangladesh.
PCRLaboratory, Ibn Sina Diagnostics and Imaging Center, Dhaka, Bangladesh.
Glob Med Genet. 2023 Aug 7;10(3):199-204. doi: 10.1055/s-0043-1771182. eCollection 2023 Sep.
Hepatitis C virus (HCV) is a causative agent that causes chronic liver diseases worldwide. It is a little, enclosed, single-stranded ribonucleic acid (RNA) virus. The recognition of the pathogenic HCV genotype is critical for the remedy of its sufferers. The aim of this study was to identify the HCV RNA genotype to decide the correct treatment of hepatitis C positive sufferers in Bangladesh. Blood samples were collected from 390 individuals and isolated RNA (60 µg) from blood plasma. Extracted RNA was used for quantitative HCV RNA, and complementary DNA (cDNA) was prepared by polymerase chain reaction (PCR) conducted by reverse transcriptase enzyme. This cDNA amplified in multiplex by RT-PCR, which was performed with specific set of primers. The HCV RNA genotype was detected 297 of 390 patients. Of the 390 test samples, 200 (51.28%) samples were from males and 190 (48.71%) were from females, with age ranging from 5 to 78 years. In all, 166 of 200 male samples and 131/190 female samples were found positive for HCV. Of these 390 participants included in the study, 213 (54.61%) were identified as genotype 3 positive, 78 (20%) as genotype 1 positive, 6 (1.53%) as genotype 6 positive, and the remaining 93 (23.85%) samples were unclassified due to low/undetected viral load. In this study, we detected the highest percentage (30.89%) of genotype 3 HCV in patients aged 51 to 60 years. The results suggested that genotype 3 HCV is frequently present in Bangladesh and it is usually responses better to interferon therapy. However, genotype 1 and 6 HCV have also been found circulating in this country, which demands longer treatments and effective control measures.
丙型肝炎病毒（HCV）是一种在全球范围内引发慢性肝病的病原体。它是一种小型、有包膜的单链核糖核酸（RNA）病毒。识别致病性HCV基因型对于其患者的治疗至关重要。本研究的目的是鉴定HCV RNA基因型，以确定孟加拉国丙型肝炎阳性患者的正确治疗方法。从390名个体采集血液样本，并从血浆中分离出RNA（60微克）。提取的RNA用于定量HCV RNA，并通过逆转录酶进行聚合酶链反应（PCR）制备互补DNA（cDNA）。该cDNA通过RT-PCR进行多重扩增，使用特定的引物组进行。在390名患者中检测到297例HCV RNA基因型。在390个测试样本中，200个（51.28%）样本来自男性，190个（48.71%）来自女性，年龄范围为5至78岁。在200个男性样本中，共有166个呈HCV阳性，在190个女性样本中有131个呈阳性。在纳入该研究的这390名参与者中，213名（54.61%）被鉴定为基因型3阳性，78名（20%）为基因型1阳性，6名（1.53%）为基因型6阳性，其余93个（23.85%）样本由于病毒载量低/未检测到而未分类。在本研究中，我们在51至60岁的患者中检测到基因型3 HCV的比例最高（30.89%）。结果表明，基因型3 HCV在孟加拉国经常出现，并且通常对干扰素治疗反应更好。然而，也发现基因型1和6 HCV在该国传播，这需要更长时间治疗和有效的控制措施。
